1-7 of 7
Chad Bjorklund
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

Michael Amatangelo, Chad Bjorklund, Jian Kang, Archana Mukhopadhyay, María Dolores Jiménez Nuñez, Lilly Wong, William Pierceall, Sagar Lonial, MD FACP, Niels W.C.J. van de Donk, Rakesh Popat, Sundar Jagannath, MD, Jeffrey Zonder, Monique C. Minnema, Albert Oriol, Jeremy Larsen, Ashraf Z. Badros, MD, Paula Rodriguez-Otero, MD PhD, Pieter Sonneveld, MD PhD, Tuong Vi Nguyen, Kevin Hong, April Sorrell, Anjan Thakurta
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-137710
Published: 2020
Journal Articles

Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

Michael Amatangelo, Chad Bjorklund, Peilin Ma, Krista Wollerman, William Pierceall, Sagar Lonial, MD FACP, Niels W.C.J. van de Donk, MD PhD, Rakesh Popat, Sundar Jagannath, MD, Jeffrey Zonder, Monique C. Minnema, Albert Oriol, Jeremy Larsen, Ashraf Z. Badros, MD, Paula Rodriguez-Otero, MD PhD, Pieter Sonneveld, MD PhD, Tuong Vi Nguyen, Kevin Hong, April Sorrell, Anjan Thakurta
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-137667
Published: 2020
Journal Articles

FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma

Michael Amatangelo, PhD, Maria Ortiz, Paola Neri, MD, Fadi Towfic, PhD, Chad Bjorklund, Jian Kang, Erica Sternberg, Nizar J. Bahlis, MD, Matthew Trotter, PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1261.
https://doi.org/10.1182/blood.V130.Suppl_1.1261.1261
Published: 2017
Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Xiaozhong Qian, Kathryn Newhall, PhD, Mark Tometsko, Chad Bjorklund, Jianglin Ma, Nizar J. Bahlis, MD, David Siegel, MD PhD, Gary J. Schiller, MD, Christy Samaras, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, Christopher S. Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Donna Reece, MD FRCP(C), Jorge Mouro, MS, Amit Agarwal, MD PhD, Faiza Zafar, MPAS, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1888.
https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888
Published: 2017
Journal Articles

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, PhD, Chad Bjorklund, Katja C. Weisel, Enrique M. Ocio, MDPhD, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau, MDPhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3109.
https://doi.org/10.1182/blood.V130.Suppl_1.3109.3109
Published: 2017
Journal Articles

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Patrick R. Hagner, Hon-Wah Man, Celia Fontanillo, Maria Wang, Suzana Couto, Mike Breider, Chad Bjorklund, Courtney G. Havens, Gang Lu, Emily Rychak, Heather Raymon, Rama Krishna Narla, Leo Barnes, Gody Khambatta, Hsiling Chiu, Jolanta Kosek, Jian Kang, Michael D. Amantangelo, Michelle Waldman, Antonia Lopez-Girona, Ti Cai, Michael Pourdehnad, Matthew Trotter, Thomas O. Daniel, Peter H. Schafer, Anke Klippel, Anjan Thakurta, Rajesh Chopra, Anita K. Gandhi
Journal: Blood
Blood (2015) 126 (6): 779–789.
https://doi.org/10.1182/blood-2015-02-628669
Published: 2015
Includes: Supplemental data
Journal Articles

IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance

Courtney G. Havens, PhD, Chad Bjorklund, PhD, Jian Kang, BS, Maria Ortiz, PhD, Celia Fontanillo, PhD, Michael Amatangelo, PhD, Ling Lu, BS, Paola E. Neri, MD PhD, Antonia Lopez-Girona, PhD, Nizar J. Bahlis, MD, Anjan Thakurta, PhD, Mathew Trotter, MD, Anita K. Gandhi, PhD, Anke Klippel, PhD, Rajesh Chopra, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3432.
https://doi.org/10.1182/blood.V124.21.3432.3432
Published: 2014